Gestational thyroid dysfunction is common and associated with maternal and child morbidity and mortality. During pregnancy, profound changes in thyroid physiology occur, resulting in different thyroidstimulating hormone (TSH) and free thyroxine (FT 4 ) reference intervals compared to the nonpregnant state. Therefore, international guidelines recommend calculating trimester-and assay-specific reference intervals per center. If these reference intervals are unavailable, TSH reference intervals of 0.1-2.5 mU/L for the first trimester and 0.2-3.0 mU/L for the second trimester are recommended. In daily practice, most institutions do not calculate institution-specific reference intervals but rely on these fixed reference intervals for the diagnosis and treatment of thyroid disorders during pregnancy. However, the calculated reference intervals for several additional pregnancy cohorts have been published in the last few years and show substantial variation.
CONTENT : We provide a detailed overview of the available studies on thyroid function reference intervals during pregnancy, different factors that contribute to these reference intervals, and the maternal and child complications associated with only minor variations in thyroid function.
SUMMARY:
There are large differences in thyroid function reference intervals between different populations of pregnant women. These differences can be explained by variations in assays-as well as population-specific factors, such as ethnicity and body mass index. The importance of using correct reference intervals is underlined by the fact that even small subclinical variations in thyroid function have been associated with detrimental pregnancy outcomes, including low birth weight and pregnancy loss. It is therefore crucial that institutions do not rely on a fixed universal cutoff concentrations, but calculate their own pregnancy-specific reference intervals.
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Thyroid dysfunction during pregnancy is common, with a prevalence of 2%-4% (1, 2 ) . Maternal thyroid dysfunction is associated with an increased risk of various adverse maternal and child outcomes, including miscarriage, intrauterine growth retardation, hypertensive disorders, preterm delivery, and a decreased child IQ (2) (3) (4) . During pregnancy, profound changes in thyroid physiology occur to provide sufficient thyroid hormone (TH) 3 to both the mother and fetus. This is particularly important during early pregnancy because the fetal thyroid starts to produce considerable amounts of TH only from approximately 20 weeks of gestation, until which time the fetus heavily depends on the maternal supply of TH. This supply of TH to the fetus, as well as increased concentrations of TH binding proteins (thyroxine-binding globulin) and degradation of TH by placental type 3 iodothyronine deiodinase necessitate an increased production of maternal TH (1, 2 ) . This requires an intact thyroid gland and adequate availability of dietary iodine and is in part mediated by the pregnancy hormone human chorionic gonadotropin, which is a weak agonist of the thyroid-stimulating hormone (TSH) receptor (5 ) . As a consequence, serum free thyroxine (FT 4 ) concentrations increase and TSH concentrations decrease from approximately the eighth week throughout the first half of pregnancy, resulting in different reference intervals for TSH and FT 4 compared to the nonpregnant state.
Given these pregnancy-related changes in thyroid physiology and the complications associated with thyroid dysfunction, it is important to determine reference intervals for normal thyroid function during pregnancy. This is crucial to identify women who would potentially benefit from treatment. For this reason, the guidelines of the Endocrine Society, American Thyroid Association, and European Thyroid Association recommend that trimester-specific reference intervals be calculated for each center (6 -8 ) . If these calculated intervals are not available in the laboratory, TSH reference intervals of 0.1-2.5 mU/L for the first trimester and of 0.2-3.0 mU/L for the second trimester are recommended (6 -8 ) . These reference interval estimations were predominantly based on the published reference intervals of 6 pregnancy cohorts (9 -14 ) . Although the center-specific reference intervals for many additional pregnancy cohorts have been published following the publication of these guidelines and show substantial differences in cutoffs for TSH, most institutions still rely on these fixed reference intervals. This is particularly relevant because even subclinical thyroid dysfunction, mostly defined according to population-based cutoffs, is associated with an increased risk of adverse maternal and child outcomes. Therefore, this review provides an overview of studies of thyroid function reference intervals during pregnancy and different factors that contribute to these intervals, as well as the clinical complications associated with minor variations in thyroid function.
Studies of Thyroid Function Reference Intervals During Pregnancy
In accordance with recommendations by the International Federation of Clinical Chemistry (15 ), international thyroid guidelines advise that reference intervals should be based on the 2.5th and 97.5th percentile of the respective population with an optimal iodine intake (6 -8 ) . In addition, each study on a specific endpoint should also incorporate a sensitivity analysis on neighboring cutoff percentiles to explore the optimal cutoff point. Analyses using a nonparametric cutoff should be performed in a sufficiently sized, nonselected population that consist of "healthy" reference individuals. Because of the high interindividual variability and skewness for TSH but also to some extent FT 4 , a minimum of approximately 400 individual measurements per partition is required as opposed to the minimum of 120 measurements recommended for standard parametric 90% coverage interval calculations (16 -19 ) . Although the term "healthy" can be interpreted in many ways for TSH and FT 4 reference interval determinations, this at least means a population free of major known factors inhibiting or stimulating thyroid function. Preferably, this population would consist of thyroid antibody [i.e., thyroid peroxidase antibody (TPOAb)-negative women without preexisting thyroid disease or other thyroid-interfering factors such as medication use or twin pregnancies]. Exclusion of TSH receptor antibody (TRAb)-positive subjects could further improve reference interval estimations, although most of the TRAb-positive subjects are also TPOAb-positive and TRAbs are far less common in the general population than TPOAbs (20 ) . Table 1 shows reference intervals for TSH and FT 4 during early pregnancy, calculated according to the international guidelines, in sufficiently sized populationbased cohorts among TPOAb-negative women (9, 14, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . For both hormones, a wide range of reference interval values has been reported, with the upper limit of TSH varying between 2.15 and 4.68 mU/L between different cohorts. Importantly, 90% of all upper limits of TSH are higher than the recommended fixed TSH cutoff concentrations of 2.5 and 3.0 mU/L for the first and second trimesters, respectively. The clinical relevance of this finding is that the use of these fixed upper limits of 2.5 mU/L and 3.0 mU/L results in significant overtreatment in euthyroid women, which may have negative effects on maternal and/or fetal outcomes. This is illustrated in Fig. 1 for a large iodine-sufficient population-based cohort in the Netherlands, where 8.6% and 4.9% of the TPOAb-negative women with TSH levels within the reference interval had a TSH concentration above 2.5 mU/L and 3.0 mU/L in the first and second trimesters, respectively (28 ) . These data underline the importance of calculating population-based pregnancy-specific thyroid parameter reference intervals, instead of using fixed upper limits of 2.5 and 3.0 mU/L.
Factors Influencing Thyroid Function Reference Intervals during Pregnancy
As illustrated in Table 1 , various commercial TSH and FT 4 assays have been used to evaluate thyroid function during pregnancy. Although previous studies have shown that the interassay differences for TSH are relatively small (r ϭ 0.91-0.98), FT 4 measurements seem much more prone to interference and have larger interassay differences (r ϭ 0.68 -0.89) (33, 34 ) . Pregnancy results in a shift of potentially interfering factors such as thyroxinebinding globulin and albumin. Not only does the extent of this shift vary per individual, it also affects measurements by each immunoassay differently. Therefore, the population differences in FT 4 concentrations can be at least partly attributed to assay-related factors. As recently suggested by Bestwick et al., TSH and FT 4 values can be expressed as multiple of medians (MoM) to interpret and compare the upper and lower limits obtained via different assays (21 ) . An MoM value is calculated by dividing each individual's value by the population median, which creates a value that is standardized for the assay median. These values are independent of interassay differences, and therefore cutoff points for different assays can be generalized more easily. Table 2 shows the calculated lower and upper limits expressed as MoM values for the same studies as Table 1 , which resulted in more uniform reference intervals. This is especially the case for FT 4 , suggesting that TSH is more subject to change by nonanalytical factors.
It has long been known that iodine is an essential component of TH that is subject to physiologic changes More studies in various trimesters of pregnancy and different ethnicities are needed to extrapolate the exact extent of these effects. The extent to which other population characteristics, such as ethnicity, body mass index (BMI), and smoking, influence TSH or FT 4 measurements is more quantifiable. These characteristics have all been associated with differences in serum thyroid parameters as well (21, 24, 25, 27, 29, 36 -43 ) . With regard to ethnicity, for a wide range of serum thyroid function tests both upper and lower limits differ according to ethnic background in the first and second trimester. La'ulu et al. showed substantial differences in TSH upper limits, ranging from 2.73 in blacks (MoM 2.81) to 3.64 mU/L in Asians (MoM 3.17), reaching borderline statistical significance (24, 25 ) . Recently, we have shown significant differences in TSH reference intervals between various ethnic groups in a population-based pregnancy cohort of European origin (see Fig. 1 in the Data Supplement that accompanies the online version of this article at http:// www.clinchem.org/content/vol61/issue5) and additionally demonstrated that these ethnic differences in thyroid parameter reference intervals may lead to considerable misclassification of thyroid disease in up to 18% of cases (39 ) .
BMI has also been associated with both TSH and FT 4 concentrations during pregnancy (21, 27, 37, 41 ) . Mannisto et al. found that among women with a BMI Ͼ30 kg/m 2 , the upper limit (95th percentile) for TSH increased from 2.86 mU/L in women with a BMI Ͻ20 kg/m 2 to 3.50 mU/L. For the same groups, they also showed that the lower limit for FT 4 (fifth percentile) decreased from 12.3 to 11.6 pmol/L, respectively (27 ) . Bestwick et al. expressed these values in MoMs and found an increase in TSH of 0.025 MoM and a decrease in FT 4 of 0.009 MoMs per 10-kg increase in body weight (21 ) . In this context it is noteworthy that the prevalence of overt hypothyroidism in morbidly obese subjects (BMI Ͼ40 kg/m 2 ) was found to be 11.8% (44 ) . The guidelines of the American Thyroid Association therefore recommend TSH screening in morbidly obese pregnant women (7 ). In line with the above, Table 1 additionally shows data on BMI, iodine status, and specific ethnic backgrounds for the various studies on thyroid function reference intervals. However, it is hard to comment on these associations from this table because these characteristics were incompletely reported in many studies.
Finally, various studies have shown that smoking has only limited effects on mean TSH and FT 4 concentrations during pregnancy (21, 29, 40, 42, 45 ) . This is illustrated by a study of 4317 Finnish pregnant women, which found that smokers had TSH concentrations identical to those of nonsmokers (1.02 mU/L), whereas there was a small difference in FT 4 concentrations (15.02 vs 15.24 pmol/L; P ϭ 0.006) (40 ) . Because effect sizes were small, it seems unlikely that population differences in smoking prevalence have any noteworthy effect on TSH and FT 4 reference intervals.
Minor Variations in Thyroid Function and the Risk of Maternal and Child Complications
The previous paragraphs showed that there are substantial differences in thyroid parameter reference intervals between populations. However, to illustrate the clinical relevance of using these population-based pregnancyspecific intervals instead of fixed or nonpregnancy reference intervals, we calculated these effects in the Generation R study (see online Supplemental Table 1 ). Women with TSH concentrations above the population-based reference interval had an increased risk of premature delivery and children with intrauterine growth retardation [small size for gestational age (SGA)], whereas women with TSH concentrations below the lower limit of this reference interval had an increased risk of hypertensive disorders (46, 47 ) . However, the use of fixed TSH cutoffs did not identify women with an increased risk of premature delivery or SGA, and the association between suppressed TSH and hypertensive disorders remained similar. This suggests that the use of fixed instead of population-based reference intervals would lead to overtreatment, particularly in women with high-normal TSH concentrations. In recent years, other studies have investigated the effects of minor subclinical variations in thyroid function on the risk of adverse maternal and child outcomes. These studies are important in the clinical context of this review because they provide insight into 
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Reviews the potential consequences of applying incorrect reference intervals to a given pregnant population. Below, we provide an overview of the effects of subclinical thyroid dysfunction during pregnancy on the risk of a number of important and well studied maternal and child complications, as summarized in Table 3 ( 46 -65 ) . A detailed discussion of studies on overt thyroid dysfunction is beyond the scope of this review because it is already known that overt thyroid dysfunction is associated with these pregnancy complications, and differences in reference interval determination particularly affect the identification of subclinical disease.
PREGNANCY LOSS
Pregnancy loss is a difficult study end point because early fetal loss naturally occurs in approximately 30% of pregnancies, of which the majority occurs even before pregnancy is clinically recognized (66 ). Negro et al. studied the relationship between thyroid function and the combined endpoint of miscarriage and stillbirth in TPOAbnegative pregnant women and concluded that women with serum TSH concentrations of 2.5-5.0 mU/L had a 6.1% risk of pregnancy loss, compared to 3.6% in women with a TSH concentration below 2.5 mU/L (49 ). However, the fact that no population-based reference intervals were calculated or sensitivity analyses done makes the 2.5 mU/L cutoff somewhat arbitrary and hard to interpret in relation to other studies. Further analyses showed a positive linear association between TSH concentrations and pregnancy loss. This is in line with the results of a Dutch cohort of 2497 pregnant women, in which it was shown that the incidence of miscarriage and fetal and neonatal death (combined into child loss) increased by 80% by every doubling of the maternal TSH concentration (67 ) . However, given the limited number of 27 cases and the heterogeneity of cases included in this group, these results should be interpreted with caution. Ashoor et al. retrospectively measured thyroid parameters in early-pregnancy samples taken from 202 pregnancies that would subsequently end in miscarriage or fetal loss and 3592 normal pregnancies (68 ) . Although the associations with subclinical thyroid dysfunction were not formally tested (i.e., abnormal TSH with still normal FT 4 ), the pregnancies complicated by child loss had higher mean TSH and lower FT 4 concentrations, and a higher prevalence of TSH concentrations Ͼ97.5th percentile and FT 4 concentrations Ͻ2.5th percentile. Finally, early-pregnancy TSH concentrations Ͼ95th percentile were associated with an increased risk of miscarriages [odds ratio (OR) 3.66, P ϭ 0.002] in an Australian pregnancy cohort, although subclinical and overt hypothyroid cases were pooled (69 ) . Taken together, these studies do suggest an increased risk of pregnancy loss in pregnancies with subclinical hypothyroidism, but large prospective studies from conception onwards are needed to determine the exact magnitude of effects.
PREMATURE DELIVERY
Premature delivery is the leading direct cause of child death in almost all high-and middle-income countries and is associated with substantial morbidity later in life (70 -72 ) . Subclinical hypothyroidism has been described as a risk factor for premature deliveries, although the pathophysiological mechanism remains poorly understood. The largest study on this association has been performed by Casey et al. on a cohort of 17 298 pregnant women presenting for prenatal care (53 ) . Subclinical hypothyroidism (TSH Ͼ97.5th percentile and FT 4 within the reference interval) was associated with a slightly increased risk of prematurity Ͻ34 weeks (4% vs 2.5%, P ϭ 0.01), borderline significantly associated with prematurity Ͻ32 weeks (2.5 vs 1%, P ϭ 0.07), and not associated with prematurity Ͻ36 weeks (7 vs 6%, P ϭ 0.39). This is in line with a later study by Cleary-Goldman et al. showing that subclinical hypothyroidism (TSH Ͼ97.5th percentile and FT 4 within the reference interval) was not associated with prematurity Ͻ37 weeks, whereas the effects on earlier premature deliveries were not investigated (54 ) . Various other studies have also investigated these relations, with conflicting results (48, 49, 52, 55, 56, 58, 69 ) . This can be partly explained by the fact that some studies pooled overt and subclinical hypothyroid cases (58, 69 ) and some included a limited number of premature deliveries (55, 56 ) , whereas others used different TSH cutoff values (49, 52 ) . We therefore studied the association between increased TSH concentrations and the risk of premature deliveries using a population-based 97.5th percentile (4.0 mU/L) and a fixed 2.5 mU/L cutoff (46 ) . Although no associations were seen with a TSH Ͼ2.5 mU/L, a 1.9-and 2.5-times increased risk of prematurity Ͻ37 and Ͻ34 weeks was seen among women with a TSH Ͼ4.0 mU/L. However, this association no longer persisted after exclusion of TPOAb-positive women or women with comorbidities. This shows that these factors confound the observed associations and underlines the importance of performing indepth analyses in a detailed cohort, taking the interfering role of various confounders into account. Far fewer data are available on the effects of subclinical hyperthyroidism on prematurity. In a study in women presenting for prenatal care, subclinical hyperthyroidism (n ϭ 433) was not associated with prematurity Յ36, Յ34, and Յ32 weeks (50 ) . This is in line with a population-based cohort study by Mannisto et al. in which subclinical hyperthyroidism (n ϭ 224 cases) was not associated with prematurity Ͻ37 and Ͻ34 weeks either (48 ) . Although 2 other population-based studies also did not find any associations, it should be noted that their analyses were limited by a small number of subclinical hyperthyroid cases (n ϭ 77 and 31) (46, 56 ) .
HYPERTENSIVE DISORDERS
Hypertensive disorders, including gestational hypertension and (pre)eclampsia, are common during pregnancy and are an important cause of maternal and fetal morbidity and mortality (73, 74 ) . Both hypo-and hyperthyroidism have vascular effects, including endothelial cell dysfunction (75, 76 ) , and are associated with an increased risk of hypertensive disorders during pregnancy. Therefore, many studies have also investigated the effects of subclinical thyroid dysfunction on the risk of hypertensive disorders. Although some studies were limited by the small number of subclinical hypothyroid or hypertensive cases (47, 55, 60, 61 ) , a few of these studies were carried out in large pregnancy cohorts (53, 54, (57) (58) (59) . In a prospective cohort study in nearly 25 000 pregnancies by Wilson et al., subclinical hypothyroidism (TSH Ͼ97.5th percentile and FT 4 2.5-97.5th percentile) was associated with a 1.6-fold increased risk of severe preeclampsia (59 ) . However, the fact that this association disappeared when only women screened before 20 weeks of gestation were included is suggestive of reverse causality (53 ) . This could be due to, for example, placental factors that are increased in preeclampsia and affect thyroid function (77 ) . Indeed, the other large studies did not find a relation between subclinical hypothyroidism in early pregnancy and the risk of subsequent hypertensive disorders (54, 57, 58 ) . The previously mentioned study by Wilson et al. also studied individuals with subclinical hyperthyroid and did not find any effects either (59 ) , as replicated in Finnish and Dutch population-based cohorts (47, 57 ) . Whereas the latter cohort was limited by a small number of subclinical hyperthyroid cases (n ϭ 62), it also was used to investigate the effects of variation in thyroid function within the population-based calculated 2.5-97.5th percentile intervals and revealed an increased risk of preeclampsia in pregnancies with highnormal FT 4 concentrations (47 ) . In contrast, a decreased risk of preeclampsia in pregnancies with high-normal FT 4 concentrations was detected in a recent study by Haddow et al., although these effects were borderline significant and P values were not corrected for multiple testing (51 ) . Therefore, future studies will have to clarify if even variation in FT 4 concentrations within population-specific reference intervals affects the risk of hypertensive disorders during pregnancy.
LOW BIRTH WEIGHT
A low birth weight can be due to either SGA or prematurity and has been associated with an increased risk of perinatal morbidity and mortality (78, 79 ) . The previously mentioned study by Cleary-Goldman et al. was the first large study to investigate the relationship between subclinical hypothyroidism and birth weight and showed no effect on the risk of newborns with very low (Ͻ2500 g) or high (Ͼ4000 g) birth weights (54 ) . A subsequent study by Mannisto et al. investigated these relations with both subclinical hypo-and hyperthyroidism in more detail and did not find effects on the risk of SGA or large size for gestational age newborns either, and it also showed no differences in mean birth weights between these groups (48 ) . A few other studies have investigated these relations with conflicting results, likely to be due to their substantially smaller sample sizes (55, 56, (61) (62) (63) . As opposed to studying subclinical thyroid dysfunction groups, Shields et al. were the first to study the relation between continuous FT 4 concentrations and birth weight in a population-based cohort after excluding women with overt thyroid dysfunction, and these authors found a statistically significant negative relation between FT 4 and birth weight (65 ) . These relations have been subsequently studied in Dutch pregnant women with FT 4 concentrations within their center-specific reference intervals, showing that high-normal FT 4 concentrations are associated not only with lower mean birth weights, but also with more SGA and Ͻ2500-g newborns (64 ) . These results have recently been convincingly replicated in the recent study by Haddow et al., which additionally showed that these children do not suffer from more labor/delivery complications (51 ) . Because a low birth weight is a risk factor for cardiovascular and psychiatric diseases in later life (78, 80 ) , it would be interesting to follow these children up for the occurrence of these complications.
Conclusions
In the last decade a large number of studies have been published on thyroid function reference intervals during pregnancy. In the current review we show that there are large differences in TSH and FT 4 reference intervals between these populations, with 90% of these studies having higher upper limits of TSH than the fixed TSH cutoff concentrations of 2.5 and 3.0 mU/L that are currently advocated in the guidelines (6 -8 ) . Nevertheless, most institutions still rely on the fixed TSH cutoff concentrations of 2.5 and 3.0 mU/L for the first and second trimesters, respectively.
The use of MoMs has illustrated that part of the differences in these intervals between populations can be explained by the use of different assays, and a number of population-specific characteristics such as ethnicity and BMI have also been identified as determinants of reference intervals. Provided that institutions determine their own population-based intervals, there is no direct need for using MoMs in clinical practice. However, the universal use of MoMs in clinical studies on the effects of thyroid dysfunction during pregnancy would certainly be useful, since it will facilitate comparison and metaanalysis of results.
We therefore conclude that institutions should not rely on a fixed universal cutoff concentration worldwide, but should calculate their own pregnancy-specific population-based reference intervals. If such reference intervals are not available, adopting population-based reference intervals from a population with similar characteristics is the best option. 
